The technology is a novel protease that reduces the ability of cells to respond to the inflammatory cytokine Tumor Necrosis Factor (TNF). High TNF levels have been linked to rheumatoid arthritis, Crohn’s disease and many types of cancers.
High levels of inflammatory cytokines such as Tumor Necrosis Factor (TNF) have been linked to numerous disease such as rheumatoid arthritis, Crohn’s disease and different cancers. Thus, it would be clinically advantageous to be able to reduce levels of TNF in patients.
Researchers at UCI have discovered a novel, naturally occurring protein, Tumor Necrosis Factor Releasing Enzyme (TRRE), that reduces the level of TNF receptors and free TNF in the blood stream. Reducing the number of TNF receptors on a cell makes the cell unable to respond to TNF, reducing inflammatory effects. Furthermore, the cleaved receptors can still bind to free TNF in the blood stream rendering the remaining TNF useless, significantly dampening the inflammatory response. This technology has the potential to help patients with many inflammatory disease types.
·Therapeutic Treatment of Rheumatoid Arthritis
·Reducing TNF level in vivo or in vitro
·Naturally occurring protease
·Highly specific for the TNF receptors·Reduces levels of both TNF receptors and free TNF in plasma
·No unwanted local or systemic effects
|United States Of America||Issued Patent||6,930,084||08/16/2005||1996-367|
|United States Of America||Issued Patent||6,911,314||06/28/2005||1996-367|
Researchers have purified TRRE In vitro and using biochemical studies have demonstrated its specificity for TNF receptors.